Innovative Therapies for Growth Hormone Deficiency: A Comprehensive Approach
DOI:
https://doi.org/10.36557/2674-8169.2024v6n4p1653-1666Keywords:
Therapies; Innovation; Growth Hormone Deficiency.Abstract
Treatment through innovative therapies for growth hormone deficiency represents an advanced approach to addressing this endocrine condition that can significantly impact patients' quality of life. These therapies offer valuable alternatives for those who do not respond adequately to conventional treatments or other available interventions. However, choosing the most suitable therapy is crucial as there are various options available, including different formulations and administration regimens. Each of these options has its own technical requirements and clinical considerations, and it is essential to examine these differences to assist healthcare professionals and patients in making informed decisions.
Exploring the different options of innovative therapies for growth hormone deficiency, it is important to consider not only efficacy in terms of improving hormone levels but also factors such as safety, tolerability, and impact on quality of life. Additionally, assessing the overall outcome of patients after starting therapy, including patient adherence, side effects, and satisfaction with treatment, is necessary. This comprehensive evaluation can provide valuable insights into the impact of therapy on daily life and patients' well-being.
Another important aspect to consider is the customization of treatment, taking into account individual patient needs and preferences, as well as their specific clinical condition. This may involve a careful assessment of the patient's medical history, expectations regarding treatment, and lifestyle. By adopting a patient-centered approach, healthcare professionals can ensure that the chosen therapy meets specific needs and provides the best possible outcomes.
In summary, studying and understanding the options for innovative therapies for growth hormone deficiency and their overall outcome evaluation are essential to ensure treatment success and patient satisfaction. By considering a variety of factors, from clinical efficacy to impact on quality of life, healthcare professionals can make more informed and personalized decisions, thus improving care and outcomes for patients with this endocrine condition.
Downloads
References
Deal, C. L., et al. (2022). Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. The Journal of Clinical Endocrinology & Metabolism, 107, e2717–e2728.
Grillo, M. S., Frank, J., & Saenger, P. (2023). Long-acting growth hormone (LAGH), an update. Frontiers in Pediatrics, 11, 1254231.
Höybye, C. (2023). Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks. Best Practice & Research Clinical Endocrinology & Metabolism, 37, 101788.
Loche, S., et al. (2024). Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study. Drug Design, Development and Therapy, 18, 667–684.
Mameli, C., Orso, M., Calcaterra, V., Wasniewska, M. G., Aversa, T., Granato, S., Bruschini, P., Guadagni, L., d’Angela, D., Spandonaro, F., Polistena, B., & Zuccotti, G. (2023). Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis. Pharmacological Research, 193, 106805.
Maniatis, A. K., et al. (2022). Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results. The Journal of Clinical Endocrinology & Metabolism, 107, e2680–e2689.
Miller, B. S., Yuen, K. C. J., et al. (2022). Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. Drug Design, Development and Therapy, 16.
Mameli, C., Orso, M., Calcaterra, V., Wasniewska, M. G., Aversa, T., Granato, S., Bruschini, P., Guadagni, L., d’Angela, D., Spandonaro, F., Polistena, B., & Zuccotti, G. (2023). Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis. Pharmacological Research, 193, 106805.
Thornton, P. S., et al. (2021). Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial. The Journal of Clinical Endocrinology & Metabolism, 106(11), 3184–3195.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Beatriz Fonseca Andrade Anjos, Ana Flávia Cerqueira Silva , Giovanna Prata Silva Melo, Ana Luiza Loureiro Prado , Yasmin Bulkool Isaac
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
